Phase III Trial Bodes Well for Investigational Treatment for Vasculitis Treatment Sending ChemoCentryx Shares up 250%

Phase III Trial Bodes Well for Investigational Treatment for Vasculitis Treatment Sending ChemoCentryx Shares up 250%

The ADVOCATE trial, sponsored by ChemoCentryx, assessed the safety of CCX168(avacopan) in inducing and sustaining remission in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). To everyone’s surprise a set of conclusive findings...

Pin It on Pinterest